ScionxBio is launched from Eleven Therapeutics, appoints Dr. Adi Gilboa-Geffen as CEO

Wednesday, July 1, 2026 | 9:00 AM ET

ScionxBio is launched from Eleven Therapeutics, appoints Dr. Adi Gilboa-Geffen as CEO

The rebrand follows a strategic horizontal split; ScionxBiofocuses the xRNA modality exclusively on long-acting therapeutics forcardio-metabolic disease under new CEO Dr. Adi Gilboa-Geffen

Cambridge, UK / Cambridge, MA / Tel Aviv - July 1,2026 - ScionxBio, a preclinical-stage RNA therapeutics company, todayannounces its emergence from stealth, after completing a strategic horizontalsplit by Eleven Therapeutics. ScionxBio will advance a groundbreaking xRNAmodality, a next-generation mRNA therapeutic, and its cardio-metabolic assetpipeline. Dr. Adi Gilboa-Geffen, Eleven’s former CTO, has been appointed asScionxBio’s Chief Executive Officer. Dr. Yaniv Erlich, co-founder and formerCEO of Eleven Therapeutics, joins ScionxBio as Co-Founder and Chairman of theBoard of Directors. Shaul Ilan, co-founder of Eleven Therapeutics, joinsScionxBio as Co-Founder, Chief Operating Officer, and Board Member.

ScionxBio is the continuation of Eleven Therapeutics’ xRNAmission: an asset-focused company with a validated platform, a definedpipeline, and a single focus - developing long-acting xRNA therapeutics forcardio-metabolic disease.

ScionxBio’s xRNA platform is built on the company’sproprietary TERÅ® technology, which uses combinatorial chemistry anddeep-learning architectures to engineer RNA molecules with significantlyenhanced structural stability and resistance to enzymatic degradation.ScionxBio is applying xRNA to cardio-metabolic disease, where long-acting,consistent protein expression has direct implications for patient burden,treatment durability, and the immunogenic risk associated with repeatadministration.

“I have spent my career building things that did notexist, always alongside great teams and great scientists. The years I spent at Eleven Therapeutics, leading the research together with Yaniv and the team,were no different. We asked whether we could engineer RNA to last. The proof isin the data: sustained in vivo protein expression lasting weeks, not days, froma single xRNA administration. Today, we have a proven modality, validated data, and a pipeline ready to move. The science phase is behind us. What comes nextis building medicines.

“Patients with chronic metabolic disease face a lifetimeof frequent dosing - and with it, accumulated immunogenic risk, side effects,and the exposure peaks and troughs that come from repeat administration.Long-acting xRNA addresses all of that. Sustained expression. Significantlyreduced immunogenic burden. A different class of medicine.”

- Dr. Adi Gilboa-Geffen, PhD, Chief Executive Officer andBoard Member, ScionxBio

“The launch of ScionxBio is a dream come true. Forseveral years, we investigated the potential of chemically modified mRNAmolecules to break new ground in genetic medicine. Now, after establishing

ScionxBio | press@scionxbio.com | www.scionxbio.com | ©ScionxBio 2026 Page 1 ScionxBio Press Release July 1, 2026

the platform, the CMC processes, and our first assets,ScionxBio is moving full steam ahead to change patients’ lives. I amparticularly thrilled that Dr. Gilboa-Geffen was selected to take the CEOposition. Having built the TERÅ® platform alongside Adi over the pastthree years, I have seen firsthand her scientific rigor, her vision, and herability to lead. I have full confidence that she is the right person to takexRNA into the clinic - and I could not be more excited about what lies aheadfor ScionxBio.”

- Dr. Yaniv Erlich, PhD, Co-founder and Chairman of theBoard of Directors, ScionxBio

“Building Eleven Therapeutics was always about creatingthe conditions for great science to become great medicine. Those conditions arenow set, and ScionxBio is the natural next step to secure success in thatjourney. To fulfill the promise of the xRNA modality, we must place patients atthe center of everything we do, and that is exactly what this evolution isabout. None of this would have been possible without Yaniv’s exceptionalleadership. His vision, integrity, and scientific conviction laid the foundationupon which ScionxBio now stands. I am deeply proud to support Adi and the boardas we take this next, defining chapter forward.”

- Shaul Ilan, Co-Founder, Chief Operating Officer andBoard Member, ScionxBio

‍